Adamas Pharmaceuticals (ADMS) Weak On High Volume

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Adamas Pharmaceuticals ( ADMS) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Adamas Pharmaceuticals as such a stock due to the following factors:

  • ADMS has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $9.2 million.
  • ADMS has traded 86,080 shares today.
  • ADMS is trading at 2.17 times the normal volume for the stock at this time of day.
  • ADMS is trading at a new low 3.15% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ADMS with the Ticky from Trade-Ideas. See the FREE profile for ADMS NOW at Trade-Ideas

If you liked this article you might like

Winning FDA Approval Isn't Always a Win

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

Adamas Skyrockets on FDA Approval for Dyskinesia Treatment - Biotech Movers

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners